Dr. Anthony is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Rose Street, CC454
University of Kentucky Medical Center
Lexington, KY 40536Phone+1 859-323-6522Fax+1 859-257-7715
Summary
- Dr. Lowell Anthony is an oncologist in Lexington, KY and is affiliated with University of Kentucky Albert B. Chandler Hospital. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 38 years. He specializes in gastrointestinal cancer and early phase (I and II) clinical trials. His major ongoing focus is with neuroendocrine neoplasms that include carcinoids, pancreatic islet cell tumors and theranostics by using somatostatin receptor imaging to predict therapeutic benefit.
Education & Training
Vanderbilt University Medical CenterFellowship, Clinical Pharmacology, 1985 - 1987- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1979 - 1982
Vanderbilt University School of MedicineClass of 1979
Certifications & Licensure
KY State Medical License 2011 - 2025
TN State Medical License 1981 - 2016
LA State Medical License 1996 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Start of enrollment: 2009 Jun 04
- A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Start of enrollment: 2014 Sep 01
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
- Join now to see all
Publications & Presentations
PubMed
- 96 citationsHepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumorsJ. G. Drougas, Lowell Anthony, Taylor K. Blair, Richard R. Lopez, J. Kelly Wright
American Journal of Surgery. 1998-05-01 - 282 citationsOctreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJoseph Rubin, Jaffer A. Ajani, William Schirmer, Alan P. Venook, Ronald Bukowski
Journal of Clinical Oncology. 1999-02-01 - 214 citations90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideDavid L. Bushnell, Thomas M. O'Dorisio, M. Sue O'Dorisio, Yusuf Menda, Rodney J. Hicks
Journal of Clinical Oncology. 2010-04-01
Press Mentions
Sylvester Recruits Aman Chauhan, M.D., to Lead Neuroendocrine Tumor ProgramMarch 16th, 2023- Dedicated Neuroendocrine Tumors Program Launched at Sylvester Comprehensive Cancer CenterMarch 16th, 2023
- UK Markey Cancer Foundation Funds First Professorship in Neuroendocrine Tumor ResearchMarch 29th, 2022
- Join now to see all
Grant Support
- Safety And Efficacy Of PTK787/ZK222584 In Patients With Neuroendocrine CancerNational Center For Research Resources2006
- Study To Evaluate The Effect Of Age And Renal Function Of OctreoscanNational Center For Research Resources2005–2006
- Study To Evaluate The Effect Of Age And Renal FunctionNational Center For Research Resources2004
- Study Comparing Venofer Intravenously To NO Iron TxNational Center For Research Resources2004
- Clinical Trial With Thymitaq Administered To PatientsNational Center For Research Resources2004
- Iodine-131 Anti-B1 Antibody For NHLNational Center For Research Resources2000–2001
- Therapeutic Indium 111 Pentetreotide In Somatostain Receptor Expressing CancersNational Center For Research Resources1998–2001
- Vu Sando LAR 2 A Tolerability &Efficacy Of Multiple Doses Of SandostatinNational Center For Research Resources1996–1997
- Comparative, 2 Way Crossover Multiple Dose Of Iv/Oral Regimen Of MesnaNational Center For Research Resources1996–1997
- Phase I Study Of Somatuline In The Management Of Lung CancerNational Center For Research Resources1993–1997
- Study Of Octreotide In The Management Of Neuroendocrine TumorsNational Center For Research Resources1992–1997
- Routes Of Ifosfamide MetabolismNational Cancer Institute1996
- Phase I Dosing Study Of Sandostatin LAR Given IM In Advanced CancerNational Center For Research Resources1995
- Routes Of Ifosfamide MetabolismNational Cancer Institute1992–1995
- Routes Of Ifosfamide MetabolismNational Center For Research Resources1993
- Multiple Dose Urinary And Serum Pharmacokinetics Of Mesna And DimesnaNational Center For Research Resources1992–1993
- Phase I Study Of Octreotide In The Management Of Neuroendocrine TumorsNational Center For Research Resources1991
- Pharmacogenetic Aspects Of Cyclophosphamide MetabolismNational Center For Research Resources1988–1990
Professional Memberships
- Member
- Member
- Member
- North American Neuroendocrine Tumor SocietyMember
- Multinational Association of Supportive Care in CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
